Related Experiment Video
Updated: Jan 9, 2026
Modeling Neural Immune Signaling of Episodic and Chronic Migraine Using Spreading Depression In Vitro
Published on: June 13, 2011
Serum inflammatory cytokines as biomarkers for predicting chronic migraine transformation: a systematic review of
Ebad Ur Rehman Syed1, Nissan Nazar1, Nalla Jaipal Reddy2
1Royal College of Surgeons in Ireland, Busaiteen, Bahrain.
Background:
Chronic migraine (CM), defined as ≥15 headache days per month, often evolves from episodic migraine. Inflammation is implicated in migraine pathogenesis, and elevated pro-inflammatory cytokines may serve as biomarkers for predicting chronification. This systematic review evaluates randomized controlled trials (RCTs) assessing serum cytokines in migraine patients to explore their potential predictive and therapeutic relevance.
Methods:
A systematic search of PubMed, Scopus, Web of Science, and clinical trial registries (to October 2024) identified English-language RCTs reporting serum cytokine levels in migraine patients. Included studies measured inflammatory cytokines [e.g., interleukins, TNF-α, and C-reactive protein (CRP)] and related them to migraine frequency or transformation. Two reviewers screened studies and extracted data on cytokine outcomes and migraine progression. Risk of bias was assessed using the Cochrane RoB 2.0 tool.
Results:
Nine RCTs (n ≈ 445) met inclusion criteria. Pro-inflammatory cytokines evaluated included IL-6, IL-1β, IL-17A, TNF-α, and CRP, while some trials also assessed anti-inflammatory markers (IL-4, IL-10, and TGF-β). Several trials involved interventions (omega-3 fatty acids, curcumin, probiotics, or exercise) and reported that reductions in pro-inflammatory cytokines corresponded with decreased migraine frequency. Notably, combination nutraceutical therapies (e.g., omega-3 plus nano-curcumin) led to significant declines in IL-1β, IL-6, and TNF-α, along with fewer migraine attacks. Aerobic exercise reduced IL-12p70 and headache days. In contrast, probiotic therapy improved symptoms without consistent cytokine changes. Although none of the RCTs were explicitly designed to predict CM transformation, patients with higher baseline cytokine levels tended to have more frequent migraines and showed stronger inflammatory modulation after treatment.
Conclusions:
Elevated pro-inflammatory cytokines are frequently observed in patients with frequent or CM and may signal increased risk of progression. Their modulation through anti-inflammatory interventions aligns with clinical improvement, suggesting that these cytokines may function as both biomarkers and therapeutic targets. Larger, longitudinal RCTs are needed to confirm their predictive value and utility in preventing migraine chronification through early inflammatory profiling.
